RA Capital Management as of June 30, 2012
Portfolio Holdings for RA Capital Management
RA Capital Management holds 29 positions in its portfolio as reported in the June 2012 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Achillion Pharmaceuticals | 8.4 | $20M | 3.2M | 6.20 | |
| Pozen | 7.6 | $18M | 2.9M | 6.23 | |
| Dyax | 7.6 | $18M | 8.5M | 2.13 | |
| ArthroCare Corporation | 6.9 | $17M | 562k | 29.28 | |
| Anacor Pharmaceuticals In | 6.5 | $16M | 2.4M | 6.49 | |
| Sangamo Biosciences (SGMO) | 5.0 | $12M | 2.2M | 5.52 | |
| Derma Sciences | 5.0 | $12M | 1.3M | 9.52 | |
| Vanda Pharmaceuticals (VNDA) | 4.8 | $11M | 2.6M | 4.40 | |
| Idenix Pharmaceuticals | 4.1 | $9.8M | 949k | 10.28 | |
| Synergy Pharmaceuticals | 3.9 | $9.4M | 2.0M | 4.75 | |
| XOMA CORP Common equity shares | 3.8 | $9.1M | 3.1M | 2.98 | |
| ACADIA Pharmaceuticals (ACAD) | 3.7 | $8.9M | 5.1M | 1.76 | |
| Coronado Biosciences Inc. Common | 3.7 | $9.0M | 1.8M | 5.05 | |
| OncoGenex Pharmaceuticals | 3.3 | $7.9M | 586k | 13.44 | |
| Synageva Biopharma | 3.1 | $7.4M | 182k | 40.56 | |
| Neurocrine Biosciences (NBIX) | 2.7 | $6.5M | 823k | 7.90 | |
| Ym Biosciences | 2.6 | $6.3M | 3.2M | 1.99 | |
| Sequenom | 2.6 | $6.1M | 1.5M | 4.06 | |
| BioCryst Pharmaceuticals (BCRX) | 2.5 | $6.0M | 1.5M | 3.97 | |
| Verastem | 2.5 | $5.9M | 606k | 9.69 | |
| Endocyte | 2.2 | $5.4M | 655k | 8.22 | |
| INC Ventrus Biosciences | 2.2 | $5.3M | 1.2M | 4.27 | |
| Senomyx | 1.9 | $4.6M | 1.9M | 2.35 | |
| Spectrum Pharmaceuticals | 1.4 | $3.3M | 211k | 15.56 | |
| ArQule | 0.8 | $1.9M | 314k | 5.93 | |
| MELA Sciences | 0.7 | $1.6M | 500k | 3.26 | |
| Repros Therapeutics | 0.3 | $705k | 78k | 9.09 | |
| Dynavax Technologies Corporation | 0.1 | $324k | 75k | 4.32 | |
| Savient Pharmaceuticals note | 0.1 | $270k | 1.0M | 0.27 |
